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We previously demonstrated inhibition of ovalbumin-induced allergic airway hyper-responsiveness in
the mouse using ES-62, a phosphorylcholine-containing glycoprotein secreted by the ﬁlarial nematode,
Acanthocheilonema viteae. This inhibition correlated with ES-62-induced mast cell desensitisation,
although the degree to which this reﬂected direct targeting of mast cells remained unclear as suppression
of the Th2 phenotype of the inﬂammatory response, as measured by eosinophilia and IL-4 levels in the
lungs, was also observed. We now show that inhibition of the lung Th2 phenotype is reﬂected in
ex vivo analyses of draining lymph node recall cultures and accompanied by a decrease in the serum lev-
els of total and ovalbumin-speciﬁc IgE. Moreover, ES-62 also suppresses the lung inﬁltration by neutro-
phils that is associated with severe asthma and is generally refractory to conventional anti-inﬂammatory
therapies, including steroids. Protection against Th2-associated airway inﬂammation does not reﬂect
induction of regulatory T cell responses (there is no increased IL-10 or Foxp3 expression) but rather a
switch in polarisation towards increased Tbet expression and IFNc production. This ES-62-driven switch
in the Th1/Th2 balance is accompanied by decreased IL-17 responses, a ﬁnding in line with reports that
IFNc and IL-17 are counter-regulatory. Consistent with ES-62 mediating its effects via IFNc-mediated
suppression of pathogenic Th2/Th17 responses, we found that neutralising anti-IFNc antibodies blocked
protection against airway inﬂammation in terms of pro-inﬂammatory cell inﬁltration, particularly by
neutrophils, and lung pathology. Collectively, these studies indicate that ES-62, or more likely small mol-
ecule analogues, could have therapeutic potential in asthma, in particular for those subtypes of patients
(e.g. smokers, steroid-resistant) who are refractory to current treatments.
 2013 Australian Society for Parasitology Inc. Published by Elsevier Ltd. Open access under CC BY license. 1. Introduction
The incidence of asthma has doubled throughout developed
countries in recent decades (Umetsu et al., 2002) such that it is
now highly prevalent in many parts of the world. The Hygiene
Hypothesis aims to explain such an increased incidence as being
a consequence of improved sanitation and hygiene in modernised
societies, with the lack of infections in childhood preventing us
from developing an immune system that responds appropriately
to environmental antigens (Strachan, 1989). This has led to the
idea that the common exposure to parasite infections in develop-
ing countries protects individuals from atopic asthma, prevalent
in developed countries. This concept has been particularly investi-
gated with respect to helminth parasites and although the situa-
tion is by no means clear-cut (Leonardi-Bee et al., 2006),Inc. Published by Elsevier Ltd.
ax: +44 0141 552 5262.
tt).
Opeevidence can certainly be found to support a protective role for
various platyhelminths and nematodes against asthma and allergy
in animal models (Harnett and Harnett, 2010).
Asthma is a chronic pulmonary disease characterised by airway
inﬂammation, acute reversible airway obstruction, bronchial hy-
per-responsiveness and high levels of serum IgE (Holgate, 1999).
The inﬂammationexhibited in asthma is generally accepted as being
associated with a Th2 phenotype immune response with inﬁltrates
of mast cells, eosinophils, macrophages and Th2 lymphocytes and
their cytokines suchas IL-5, IL-4 and IL-13beingpresent in increased
amounts in the lungs (Busse and Lemanske, 2001). IL-5 induces
eosinophils to differentiate from bone marrow progenitor cells
and to move to the lung and expand to form a local IL-4-producing
innate cell population. This further ampliﬁes the Th2 cytokine envi-
ronment (Chen et al., 2004), resulting in increased IgE production
(Bossie et al., 1987) which, when found on the surface of mast cells,
is centrally involved in the pathogenesis of asthma (Busse and
Lemanske, 2001). Collectively, these responses ultimately result in
airway hyper-responsiveness (AHR) and remodelling.n access under CC BY license. 
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taining glycoprotein discovered in the rodent ﬁlarial nematode
Acanthocheilonema viteae (reviewed in Harnett and Harnett, 2010).
ES-62 possesses a number of anti-inﬂammatory properties (Whelan
et al., 2000; Goodridge et al., 2001; Harnett and Harnett, 2010) and
consistent with this, we have shown that prophylactic ES-62 treat-
ment is protective in a mousemodel of Th1/Th17-mediated inﬂam-
matory autoimmune disease, collagen-induced arthritis (McInnes
et al., 2003). Similarly, and consistent with the proposal that hel-
minth infections may protect from allergic inﬂammatory diseases,
we found that the anti-inﬂammatory actions of ES-62 extended to
inhibitionof inﬂammation exhibited in the lungs in themurine oval-
bumin (OVA)-induced model of allergic asthma (Melendez et al.,
2007). These data suggest that ES-62 has therapeutic potential in
the treatment of asthma and hence it is important to elucidate its
mechanism of action. Prophylactic exposure to ES-62 reduced dis-
ease severity and progression as indicated by histological analysis
of lung pathology andwhole-body plethysmography determination
of airway hyper-reactivity and remodelling. The protection ob-
served in mice correlated with ES-62-induced desensitisation of
mast cells, which have been implicated in airway remodelling
(Carter and Bradding, 2011; Gilﬁllan and Beaven, 2011), and also
with suppression of the Th2 phenotype of airway inﬂammation,
the latter as evidenced by reduced eosinophilia and IL-4 levels in
the lungs (Melendez et al., 2007). Therefore, we investigated the
mechanisms by which ES-62 acts to suppress the Th2-mediated
parameters of OVA-induced airway disease.2. Materials and methods
2.1. Mice and reagents
Six to 8 week old female BALB/c mice were purchased from Har-
lan Olac (Bicester, UK) and maintained at the Universities of Glas-
gow and Strathclyde, UK. All procedures were conducted in
accordance with Home Ofﬁce, UK animal guidelines and with the
approval of the local ethical committees. Puriﬁed, endotoxin-free
ES-62 from the rodent ﬁlarial nematode, A. viteae, was produced
as described previously (Wilson et al., 2003). Neutralising anti-
IFNc antibodies were puriﬁed using Protein G Sepharose, Fast Flow
(Sigma Aldrich, Dorset, UK) from cell line XMG1.6, which was a
kind gift from Prof. Richard Grencis at the University of Manches-
ter, UK. The IgG isotype control (rat IgG1) was obtained from Bio X
Cell (West Lebanon, NH, USA).2.2. Allergic airway model
Allergic airway inﬂammation was induced as described previ-
ously (McKay et al., 2004). Brieﬂy, 6–8 week old female BALB/c
mice were sensitised to OVA by i.p. injection of 100 lg of OVA in
200 ll of 1% alum (Alhydrogel; Brenntag Biosector, Fredriksund,
Denmark) on days 0 and 14. On day 14, mice were challenged by
the intranasal (i.n.) route with 50 lg of OVA in 30 ll of PBS (endo-
toxin-free, Lonza, Slough, UK) after anaesthesia was induced with
isoﬂurane. On days 25, 26 and 27 mice were anaesthetised and
re-challenged i.n. with 50 lg of OVA in 30 ll of PBS. Control mice
received PBS in place of OVA. Mice were subjected to euthanasia
on day 28 by lethal i.p. injection of avertin (1,1,1-tribromoethanol)
dissolved in iso-amyl alcohol and diluted 1 in 40 in PBS, and bron-
choalveolar lavage (BAL) and lung histology were performed as de-
scribed previously (Melendez et al., 2007). There were four
experimental groups denoted: PBS (control), ES-62, OVA and
OVA + ES-62. ES-62 and OVA + ES-62 mice received 2 lg of ES-62
in 100 ll of PBS, by s.c. injection in the scruff of the neck on days
2, 12, 25 and 27. Mice in the control and OVA groups receivedPBS on these days. The concentration of ES-62 used has been
shown to be likely to give serum levels equivalent to those found
for PC-containing molecules during ﬁlarial nematode infection of
humans (Lal et al., 1987; Wilson et al., 2003). For the studies using
neutralising anti-IFNc antibodies, mice in OVA and OVA + ES-62
groups were i.p. injected with either 150 lg of anti-IFNc or isotype
control IgG (both endotoxin free) in 150 ll of PBS on days 1, 15 and
26. The control IgG antibody had no signiﬁcant effect on any of the
OVA responses tested (results not shown).
2.3. Ex vivo lymph node cultures
Lungs were dissected and the peribronchial draining lymph
nodes (DLNs; thoracic) harvested. DLN cells were cultured in RPMI
1640 medium at 106 cells/ml with 10% FBS, penicillin (100 U/ml),
streptomycin (100 lg/ml), L-glutamine (2 mM), 2-mercap-
toethanol (50 lM), 1% non-essential amino acids and sodium pyru-
vate (1 mM) (all from Gibco Life Technologies, Paisley, UK). Cells
were cultured in medium alone or in medium containing antigen
(OVA at 500 lg/ml) or concanavalin A (ConA, 3 lg/ml) for the
72 h culture period. For proliferation analysis, cells were pulsed
with [3H] thymidine (0.5 lCi/well; Amersham Pharmacia Biotech,
Little Chalfont, UK) for the last 4 h of culture. For cytokine analysis,
samples were centrifuged at the end of the culture period for 5 min
at 400g and the supernatant removed and stored at 20 C until
further analysis.
2.4. Cytokine and antibody detection
Cytokines in culture supernatants and serum were analysed
using ELISA kits (BD Biosciences, Oxford, UK apart from that for
IL-17: BioLegend Ltd., Cambridge, UK) or by employing the Lumin-
ex system (also used for all other cytokines, chemokines and
growth factors referred to) with a 20-Multiplex inﬂammatory cyto-
kine kit (Biosource, Invitrogen, Paisley, UK) according to manufac-
turers’ instructions. The lower limit of detection for all cytokines
apart from IL-17 (15 pg/ml) was 20 pg/ml for ELISA and 5 pg/ml
for IL-4 and IL-13, 10 pg/ml for IL-5, 15 pg/ml for IL-10 and 1 pg/
ml for IL-17 and IFNc by Luminex. Bio-plex Manager software with
ﬁve parametric curve ﬁtting was used for data analysis (Bio-Rad
Laboratories Inc., USA). Total IgE and OVA-speciﬁc IgG1, IgG2a
and IgE levels were measured in serum by ELISA (BD Biosciences,
UK) following the manufacturer’s instructions using Maxisorp ELI-
SA plates (Nunc, Roskilde, Denmark).
2.5. In vitro dendritic cell (DC)-T cell cocultures
Bone marrow-derived dendritic cells (bmDCs) were prepared as
described previously (Goodridge et al., 2004, 2005). Brieﬂy, bone
marrow cells were cultured in RPMI-1640 complete medium con-
taining 2 mM L-glutamine, 50 U/ml of penicillin, 50 lg/ml of strep-
tomycin, 10% FCS (Invitrogen) supplemented with 10% conditioned
medium generated by the GM-CSF-secreting X63 myeloma cell line
and 50 lM 2-mercaptoethanol, for 6 days at 37 C/5% CO2, with
fresh medium supplied on day 4. On day 7, the loosely adherent
immature bmDCs were harvested, pulsed with peptide antigen
(Ag) (OVA332–339) and cocultured (2.5  104 cells) with OVA-spe-
ciﬁc CD4+CD62L+ T cells (2  105 cells) from DO.11.10/BALB/c mice,
puriﬁed using CD4+ T cell negative selection and enrichment for
naïve CD62Lhigh cells (Miltenyi Biotec Ltd., UK) as described previ-
ously (Whelan et al., 2000; Marshall et al., 2005). Cells were cocul-
tured in a total volume of 1 ml of RPMI 1640 medium
supplemented with 10% FBS, penicillin (100 U/ml), streptomycin
(100 lg/ml), L-glutamine (2 mM), 2-mercaptoethanol (50 lM), 1%
non-essential amino acids and sodium pyruvate (1 mM) in 24 well
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moved and stored at 20 C for future cytokine analysis.
2.6. Analysis of intracellular cytokine production and transcription
factor expression
Intracellular cytokine production was assessed using the Cell
Fixation and Permeabilisation solutions and protocols provided
by eBioscience (Hatﬁeld, UK) as described previously (Pineda
et al., 2012). Brieﬂy, DLN cells were stimulated with RPMI-1640
medium or 500 ng/ml of phorbol 12-myristate 13-acetate (PMA)
plus 500 ng/ml of ionomycin and 1xBrefeldin A (eBioscience, UK)
for 4 h at 37 C with 5% CO2. Cells were stained with Fixable Viabil-
ity Dye eFluor 780 (eBioscience) prior to staining for cell surface
phenotypic markers using anti-CD4-PerCP or anti-CD8-FITC (both
BD Pharmingen, UK). The cells were then ﬁxed and permeabilised
before staining with the relevant cytokine-speciﬁc APC-conjugated
(anti-IL-10: BD Pharmingen; anti-IFNc and anti-IL-17: Biolegend)
or PE-conjugated (anti-IL-4, BD Pharmingen) antibody. Intracellu-
lar Foxp3 and RORct expression in DLN cells was similarly ana-
lysed using the APC-conjugated Foxp3- and PE-conjugated
RORct-speciﬁc antibodies, and staining buffer sets and protocols
from eBioscience.
2.7. Quantitative real time PCR (qRT-PCR)
qRT-PCR procedures were carried out according to the
manufacturer’s instructions (Applied Biosystems, Carlsbad CA,
USA). IL-4, IL-17, IFNc and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) levels were tested using Applied Biosystems assay
kits, Mm00445259_m1, Mm00439619_m1, Mm01168134_m1 and
Mm99999915_g1. All samples were examined in triplicate and data
analysed by StepOne software using the comparative CT (DDCT)
(Applied Biosystems) with values for samples being normalised to
the reference reporter GAPDH. Lungs stored in RNAlater (Qiagen,
Crawley, UK) were transferred into RTL plus buffer (Qiagen) supple-
mented with b-mercaptoethanol and homogenised with the Tissu-
eRuptor (Qiagen). The homogenate was then centrifuged for 3 min
at maximum speed and the lysate was used to extract RNA using a
RNAeasy plus kit (Qiagen). Up to 1 lg of RNA was reverse tran-
scribed using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) and 50 ng of RNA was used per qRT-PCR.
2.8. Analysis of lineage-speciﬁc transcription factor expression in tissue
sections
Brieﬂy, tissue sections (6 lm) were incubated in acetone for
20 min, air dried and rehydrated with PBS containing 1% goat ser-
um before being incubated in blocking reagent containing 6% BSA,
10% goat serum and 1% Fc-block. For staining of transcription fac-
tors, 0.1% (v/v) TritonX (Sigma) was used whilst for IgE, 0.5% sapo-
nin was added to all buffers. Avidin solution (Vector Laboratories
Ltd., Peterborough, UK) was added for 15 min to block unmasked
endogenous biotin, then biotin solution (Vector Laboratories) was
added to block excess avidin. Puriﬁed or biotinylated primary anti-
bodies and isotype controls were added either for 1 h at room tem-
perature (surface marker) or overnight at 4 C (intracellular
staining). Fluorochrome conjugated secondary antibodies or strep-
tavidin conjugates were added for 1 h before mounting using Vec-
tashield. Images (20 magniﬁcation) were captured using a
Hammamatsu camera and analysed using Openlab imaging soft-
ware (Improvision, Coventry, UK). Quantitative laser scanning
cytometry (LSC) analysis was performed as described previously
(Adams et al., 2004; Morton et al., 2007) where standard cell con-
tours were set to determine individual transcription factor-positive
T cells. Tissue maps were generated from these data and the num-ber and percentage of transcription factor-positive T cells located
within the T cell area were determined using WinCyte software
(CompuCyte Corp, Essex, UK).
2.9. Statistical analysis
Statistical analysis was determined by t-test and ANOVA or
Kruskal–Wallis (non-parametric data) with Bonferroni or Dunn
post-tests, respectively, as appropriate. P values of ⁄ 60.05, ⁄⁄ 60.01
and ⁄⁄⁄ 60.001 were used to denote signiﬁcance.3. Results
3.1. ES-62 suppresses inﬁltration of a heterogeneous population of
inﬂammatory cells into the lungs of mice undergoing OVA-induced
airway inﬂammation
Prophylactic exposure to ES-62 in vivo reduces lung pathology
and, speciﬁcally, eosinophilia in the mouse OVA-induced airway
inﬂammation model, thereby protecting against OVA-induced
hypersensitivity (Melendez et al., 2007). These results are now
conﬁrmed and extended by our showing that in addition to pre-
venting eosinophilic inﬂammation (Fig. 1A), ES-62 also signiﬁ-
cantly prevented inﬁltration of the lungs by neutrophils (Fig. 1B)
and lymphocytes (Fig. 1C). ES-62 also tended to reduce the num-
bers of macrophages and total cells in the BAL ﬂuid (BALF) but this
did not reach statistical signiﬁcance (Fig. 1D, E).
3.2. ES-62 suppression of lung inﬂammation is associated with reduced
local Th2 cytokine responses
To address whether such protection reﬂects immunomodula-
tion of polarised Th responses during OVA-induced airway inﬂam-
mation, the effect of in vivo exposure to ES-62 on subsequent
peribronchial DLN recall responses to OVA ex vivo was determined.
Firstly, cell proliferative responses were analysed and it was noted
that whilst DLN cells from mice that had received the airway
inﬂammation protocol (OVA and OVA + ES-62 groups) showed ele-
vated basal levels of proliferation relative to those from PBS (con-
trol) or ES-62 groups (⁄⁄⁄P 6 0.001; Fig. 2A), stimulation with OVA
ex vivo strongly enhanced this proliferation (⁄P 6 0.05 for OVA
groups and ⁄⁄⁄P 6 0.001 for OVA + ES-62 groups) but there were
no signiﬁcant differences found between the responses of the
OVA and OVA + ES-62 groups. ES-62 treatment alone had little ef-
fect on cytokine production in DLN cells (Fig. 2B–F), however, and
consistent with OVA-induced inﬂammation reﬂecting a Th2 phe-
notype, IL-4, IL-5, IL-13 and IL-10 production was detected in cells
from mice undergoing OVA-induced airway inﬂammation and this
was found to be reduced in cells from such mice exposed to ES-62
in vivo (Fig. 2B–E). Conversely, exposure to ES-62 did not suppress
OVA-speciﬁc IFNc production (Fig. 2F). To support these ﬁndings of
suppression of Th2 responses, we undertook an experiment mea-
suring cytokine levels in serum samples and whilst the low levels
of IL-5 detected in mice from the OVA group were signiﬁcantly ele-
vated relative to mice treated with PBS or ES-62 alone, the levels in
the OVA + ES-62 group were not signiﬁcantly different from the
control groups (Fig. 2G). However, serum levels of IL-4, IL-10, IL-
13 and IFNc in all groups were found to be below the detection le-
vel of the assay in use. It was also not possible to detect eotaxin.
The chemokines, MCP-1, MIG (CXCL9) and MIP-1a, and the growth
factor, FGF, which have been implicated in the inﬂammation and
increased angiogenesis associated with remodelling in asthma
(Linden, 2003; Kolls and Linden, 2004; Havaux et al., 2005; Bosse
et al., 2006; Feltis et al., 2006) were detected; however, serum
levels of these inﬂammatory mediators were not found to be sig-
Fig. 1. The phosphorylcholine-containing glycoprotein, ES-62, inhibits eosinophil, neutrophil and lymphocyte inﬁltration of the lungs in the murine ovalbumin (OVA)-
induced airway inﬂammation model. Differential eosinophil (A), neutrophil (B), lymphocyte (C), macrophage (D) and total (E) bronchoalveolar lavage ﬂuid (BALF) cell counts
in individual mice from each of the four treatment groups where, for A–D, n = 32 for PBS; n = 22 for ES-62; n = 51 for OVA and n = 38 for OVA + ES-62 groups and for E, n = 42
for PBS; n = 24 for ES-62; n = 59 for OVA and n = 44 for OVA + ES-62 groups. The bar represents the median value of the group and ⁄P 6 0.05 or ⁄⁄P 6 0.01 for OVA compared
with OVA + ES-62 groups.
214 J. Rzepecka et al. / International Journal for Parasitology 43 (2013) 211–223niﬁcantly different amongst the four treatment groups (results not
shown). The Th2-suppressive effects of ES-62 on OVA-treated mice
were Ag-speciﬁc because they were not mirrored in the mitogen
(ConA)-induced proliferation and cytokine responses of DLN cells
(results not shown).
3.3. ES-62 treatment inhibits IgE production
As antibodies, especially those of the signature Th2 isotype,
IgE, have great inﬂuence in directing and enhancing the inﬂam-
matory immune response in allergic airway disease (Busse and
Neaville, 2001; Busse and Lemanske, 2001), it was next deter-
mined whether the anti-inﬂammatory action of ES-62 was
reﬂected by a change in the antibody proﬁle in vivo. Thus, sera
from all groups of mice were analysed in vitro for total IgE and
OVA-speciﬁc IgG1, IgG2a and IgE content. Whilst IgE levels were
elevated in the OVA, relative to the control and ES-62 groups
(Fig. 3A, B), this elevation in antibody production was
signiﬁcantly inhibited by prophylactic treatment with ES-62
(OVA + ES-62 group) (P 6 0.001 for both total and OVA-speciﬁc
IgE). However, analysis of sera IgG demonstrated that levels of
OVA-speciﬁc IgG1 and IgG2a antibody isotypes in mice that had
received the OVA administration protocol were not inﬂuenced
by exposure to ES-62 (Fig. 3C, D). Consistent with the observed
reduction in serum IgE levels, lower levels of IgE expression could
be detected in DLN cells from OVA + ES-62, relative to OVA, mice
(Fig. 3E).
3.4. Exposure to ES-62 in vivo modulates the Th1/Th2 balance in OVA-
induced airway inﬂammation
To investigate whether ES-62 was suppressing the development
of Th2 responses in OVA-induced airway inﬂammation by induc-
tion of regulatory T (Treg) cells, DLN tissue sections were stained
for expression of the signature Treg, Th1 and Th2 transcription fac-
tors, Foxp3, Tbet and GATA3, respectively (Fig. 3F), and imaged and
quantitatively analysed by LSC (Adams et al., 2004; Morton et al.,2007). Consistent with the observed inhibition of Th2 responses,
the number of cells expressing GATA3 was reduced essentially to
zero following ES-62 exposure but this did not appear to reﬂect
suppression by Treg cells as the number of Foxp3 positive cells
was also slightly reduced in the DLN cells from ES-62-treated mod-
el mice (Fig. 3F). These data were corroborated by ﬂow cytometric
analysis of DLN cells from an independent experiment that showed
no substantial differences in the levels of Foxp3+CD4+Tregs
amongst the different treatment groups (Fig. 3G) or in production
of the Treg effector cytokine, IL-10, by DLN cells (Fig. 3H). By con-
trast, however, there was an appearance of cells expressing Tbet in
DLN sections from the ES-62-treated OVAmodel mice (Fig. 3F) sug-
gesting that ES-62 might act by resetting the Th1/Th2 balance in
OVA-induced airway inﬂammation. Likewise, data from an inde-
pendent experiment showed that exposure to ES-62 in vivo re-
sulted in increased levels of spontaneous (Fig. 3I) IFNc
production by DLN cells from mice undergoing OVA-induced air-
way inﬂammation, with the OVA + ES-62 group exhibiting an
approximately twofold increase in the small proportion of DLN
cells producing IFNc, relative to those from OVA mice, which
exhibited comparable levels to those of naïve animals. Consistent
with our previous ﬁndings that exposure to ES-62 alone induces
a weak Th2 phenotype in naïve healthy mice (Whelan et al.,
2000; Marshall et al., 2005), the lowest levels of spontaneous
IFNc-producing cells were observed in DLNs from the ES-62 group.
Moreover, the OVA + ES-62 group contained the highest percent-
age of IFNc-producing cells (and the highest expression of IFNc
within cells) following stimulation with PMA plus ionomycin
(Fig. 3J) whilst the lowest proportion of such cells was found in
the DLN from the control (PBS) group of mice.3.5. Neutralising anti-IFNc antibodies inhibit the protection against
airway inﬂammation afforded by ES-62
To address whether the ES-62 mediated stimulation of IFNc
production played a role in the protection afforded by the helminth
product by resetting the Th1/Th2 balance, the effect of neutralising
Fig. 2. In vivo treatment with the phosphorylcholine-containing glycoprotein, ES-62, inhibits draining lymph node (DLN) cell antigen-speciﬁc Th2 cytokine production but
not antigen-speciﬁc proliferation ex vivo. Lung DLN (thoracic) cells from individual mice within each in vivo treatment group were pooled and cultured with medium alone or
ovalbumin (OVA) (500 lg/ml) for 72 h. Cell proliferation was measured by [3H] thymidine uptake and data (A) are expressed as mean ± S.D. (n = 3 replicate cultures) and are
from one experiment representative of two. Culture supernatants IL-4 (B), IL-5 (C), IL-13 (D), IL-10 (E) and IFNc (F) were measured for each group and data are expressed as
mean concentrations ± S.D., n = 3 replicate cultures, where ⁄⁄⁄P 6 0.001, apart from IL-4 and IFNc which were measured as duplicate samples by Luminex, and represent
single data sets representative of at least two independent experiments apart from IL-13 which was only measured in a single experiment to corroborate the decrease in the
very low levels of IL-4 observed in that model. (G) The mean values of triplicate serum (obtained day 28) values from individual mice (n = 6) are shown where the bar
represents the mean of the group and the OVA, but not OVA + ES-62, group shows signiﬁcantly elevated levels of IL-5 (⁄P 6 0.05) relative to the PBS and ES-62 control groups.
J. Rzepecka et al. / International Journal for Parasitology 43 (2013) 211–223 215
Fig. 3. Exposure to the phosphorylcholine-containing glycoprotein, ES-62, in vivo does not modulate ovalbumin (OVA)-induced elevation of IgG1 and IgG2a but inhibits IgE
and suppresses Th2 cells. Serum samples from each mouse were obtained on day 28. Samples were analysed by ELISA for OVA-speciﬁc IgE (A) and total IgE (B), at 1/80 and 1/
200 dilutions, respectively, and OVA-speciﬁc IgG1 (C) and IgG2a (D) over the full titration range where data for each group are presented as the mean ± S.E.M. (n = 6 mice/
group) and ⁄⁄⁄P 6 0.001, OVA + ES-62 compared with the OVA group. The data are from one experiment representative of two. In E, draining lymph nodes (DLN) cells from
each of the four treatment groups were stained for expression of IgE. (F) DLN sections from OVA and OVA + ES-62 groups were stained for B220+ B cells, CD3+ T cells and for
the indicated transcription factor (either GATA3, Foxp3 or Tbet) and the transcription factor positive cells were quantiﬁed within the T cell regions. Exemplar tissue maps
from a single experiment of DLNs from OVA and OVA + ES-62 groups displaying the relevant distribution of such transcription factor positive cells (red) within the T cell
paracortical region (white) surrounded by B220+ B cells (blue) and their quantitation of numbers of the relevant transcription factor positive T cells by laser scanning
cytometry (LSC) are shown, together with an exemplar relocated image of a portion of the section from the OVA group where Foxp3 is stained in red and CD3, green (F). In an
independent experiment, the proportions of Foxp3-expressing unstimulated CD4+ T cells from the DLN of pooled mice from the four treatment groups are shown, with the
percentage of cells in the Foxp3+CD4+ quadrant annotated to the right of the plots (G). Pooled DLN cells from the four treatment groups were cultured with medium (I) or
phorbol 12-myristate 13-acetate (PMA) plus ionomycin (IONO) (H, J) in the presence of Brefeldin A before staining for intracellular expression of IL-10 (H) or IFNc (I, J) prior to
FACS analysis: cytokine expression (y-axis) was plotted against side scatter (x-axis) and the percentage of DLN cells in the cytokine positive gate is shown and annotated to
the right of the plots. (J) The Mean Fluorescence Intensity (MFI) values for IFNc production for the four treatment groups are PBS: 24,701; ES-62: 21,915; OVA: 23,439 and
OVA + ES-62: 27,596. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
216 J. Rzepecka et al. / International Journal for Parasitology 43 (2013) 211–223
Fig. 4. Exposure to the phosphorylcholine-containing glycoprotein, ES-62, in vivo increases CD4 and CD8 IFNc responses during murine ovalbumin (OVA)-induced airway
inﬂammation. (A) The proportion of draining lymph node (DLN) cells expressing IFNc following stimulation with phorbol 12-myristate 13-acetate (PMA) plus ionomycin in
the indicated treatment groups by individual mice (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled
from two independent experiments). The bar represents the mean of the group and the OVA + ES-62 + IgG, but not OVA + IgG, group is signiﬁcantly different from the PBS
group (grey ⁄⁄P 6 0.01). In an independent experiment, the cytokine expression (y-axis) by cells from pooled DLN from the indicated groups was analysed and the proportions
of IFNc-producing cells in the lymphocyte gate of DLN cells from mice from the OVA and OVA + ES-62 groups that were CD4+ (B, C) or CD8+ (D, E) following stimulation with
medium (B, D) or PMA plus ionomycin (C, E) are shown. The proportions (F) and numbers (G) of PMA plus ionomycin-stimulated CD4 cells expressing IFNc in the DLN of
individual mice from the indicated groups (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from
two independent experiments) are shown where the bar represents the mean of the group and the OVA + ES-62 + IgG group demonstrates signiﬁcantly elevated levels of IFNc
production relative to the PBS control group (where ⁄P 6 0.05). (H) The proportions of PMA plus ionomycin-stimulated CD4+ cells expressing IFNc in the DLN of individual
mice from the indicated groups (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from two
independent experiments) are shown where the bar represents the mean of the group and no signiﬁcant differences are detected.
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inﬂammation was investigated in two further independent exper-
iments. It was noted (Fig. 4A) that a signiﬁcantly greater propor-
tion of PMA plus ionomycin-stimulated DLN cells from the
OVA + ES-62, but not OVA, group treated with the control IgG ex-
pressed IFNc than those from the PBS control group. However, this
was not found to be the case in the presence of the neutralising
anti-IFNc antibodies (Fig. 4A). The expanded population of IFNc-
producing cells observed in the OVA + ES-62 mice (Fig. 3I, J) re-
ﬂected increases in both IFNc-producing CD4+ (Fig. 4B, C) and
CD8+ (Fig. 4D, E) T cell populations. Analysis of the data from the
two neutralising antibody studies showed that whilst the propor-
tion (Fig. 4F) and number (Fig. 4G) of PMA plus ionomycin-
stimulated CD4 DLN cells (predominantly CD8+ T cells) producing
IFNc were signiﬁcantly higher in the IgG-treated OVA + ES-62, but
not OVA, group relative to the PBS control group, this effect was
abolished by exposure to the neutralising anti-IFNc antibodies.
However, the proportion (Fig. 4H) of CD4+ DLN cells expressing
IFNc following stimulation with PMA plus ionomycin was not sig-
niﬁcantly different in the IgG-treated OVA + ES-62 group, relative
to the OVA group, suggesting that the immunomodulatory IFNc
elicited by ES-62 was predominantly derived from CD4 DLN cells,
which are likely to be Tbet+CD8+ T cells (Szabo et al., 2002). Collec-
tively, these data indicate that the neutralising anti-IFNc antibod-
ies were effective in vivo and suggest that blocking of this cytokineabrogates the resetting of the Th1/Th2 phenotype observed in
OVA + ES-62 mice.
Importantly, therefore, and supportive of a role for ES-62 stim-
ulated IFNc in protecting against OVA-induced airway inﬂamma-
tion, the OVA + ES-62 group of mice treated with neutralising
anti-IFNc antibodies showed elevated levels of neutrophil
(Fig. 5A), macrophage (Fig. 5B) and lymphocyte (Fig. 5C) inﬁltration
of the BALF relative to those treated with control IgG. Moreover,
although it did not reach statistical signiﬁcance, the level of esoin-
ophils also increased (Fig. 5D). In addition, analysis of lung pathol-
ogy revealed higher levels of cellular inﬁltration and airway
remodelling in the OVA + ES-62 group treated with the neutralising
antibody, relative to the isotype control group (Fig. 5E).
It appeared that the effect generated by anti-IFNc treatment re-
ﬂected, at least in part, that this cytokine does indeed act to reset
the Th1/Th2 balance as although, as expected, ES-62-treated mice
induced more IL-4-producing DLN cells than those of the control
PBS group, the OVA + ES-62 group exhibited a lower proportion
of IL-4-producing DLN cells than of the OVA group (Fig. 6A) in re-
sponse to stimulation with PMA plus ionomycin. Moreover, analy-
sis of data for individual mice from the two neutralising antibody
experiments revealed that whilst the number of spontaneously-
(Fig. 6B) and PMA plus ionomycin-stimulated (Fig. 6C) IL-4-
producing DLN cells was signiﬁcantly elevated in the OVA + IgG,
but not OVA + ES-62 + IgG, group relative to the control PBS mice,
Fig. 5. Neutralising anti-IFNc antibodies prevent ES-62-mediated protection against cellular inﬁltration in murine ovalbumin (OVA)-induced airway inﬂammation.
Differential neutrophil (A), macrophage (B), lymphocyte (C) and eosinophil (D) bronchoalveolar lavage ﬂuid (BALF) cell counts for individual mice in each of the indicated
treatment groups (PBS, n = 8; OVA + IgG, n = 10; OVA + ES-62 + IgG, n = 8; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 10; pooled from two independent
experiments) are shown where the bar represents the median of the group and black ⁄P 6 0.05 and ⁄⁄P 6 0.01 are for OVA + ES-62 + IgG compared with OVA + ES-62 + anti-
IFNc groups whilst grey ⁄⁄P 6 0.01 and ⁄⁄⁄P 6 0.001 are for PBS compared with the indicated treatment group. (E) Representative H & E sections from the OVA + ES-62 + IgG
(n = 3 mice) and the OVA + ES-62 + anti-IFNc (n = 3 mice) groups. Images were captured using an Olympus BX41 microscope mounted with an Olympus U-CMAD3 camera
and Cell-B2.0 software. Images are at 10 magniﬁcation and include automatic yellow scale bar (200 lm) at the bottom right corner of image.
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62 group exhibited signiﬁcantly higher numbers of such cells
(Fig. 6B, C). A similar pattern of IL-4 production was shown for both
CD4 (Fig. 6D, spontaneous; Fig. 6E, PMA plus ionomycin) and
CD4+ T cells (Fig. 6F, PMA plus ionomycin), the latter subtype spon-
taneously expressing IL-4 at signiﬁcantly higher levels in response
to anti-IFNc treatment (Fig. 6G), than to treatment with control
IgG.
3.6. ES-62-mediated resetting of the Th1/Th2 balance in OVA-induced
airway inﬂammation is associated with suppression of Th17/IL-17
responses
Members of the IL-17 family of cytokines, including IL-17
(IL-17A and IL-17F) and IL-25 (IL-17E) have recently been reported
to play key roles in promoting Th2 polarisation and eosinophil
(Dias and Banerjee, 2012; Murdock et al., 2012), neutrophil(Iwakura et al., 2011) and macrophage recruitment (Barin et al.,
2012) leading to AHR (Hellings et al., 2003; Linden, 2003;
Kawaguchi et al., 2004; Schnyder-Candrian et al., 2006; Pichavant
et al., 2008; Traves and Donnelly, 2008; Wang and Liu, 2008; Lajoie
et al., 2010; Wang et al., 2010; Iwakura et al., 2011). In addition,
Th17 cells have been shown to counter-regulate Th1 responses
(Durrant and Metzger, 2010; Jager and Kuchroo, 2010). Thus it
was investigated whether ES-62-mediated suppression of patho-
logical Th2- and induction of counter-regulatory IFNc-responses
correlated with targeting of IL-17 production (Fig. 7). Analysis of
the small populations of IL-17-producing DLN cells indicated that
whilst those from the PBS, ES-62 and OVA + ES-62 groups exhibited
comparable proportions of DLN cells spontaneously producing IL-
17, this was slightly elevated in the OVA group (Fig. 7A). Similarly,
the OVA mice exhibited the highest levels of such cells in response
to PMA plus ionomycin but this population was substantially
reduced in the OVA mice exposed to ES-62 in vivo (Fig. 7B). Such
Fig. 6. Neutralising anti-IFNc antibodies modulate IL-4 responses in ES-62-treated mice undergoing ovalbumin (OVA)-induced airway inﬂammation. Draining lymph node
(DLN) cells from the four indicated treatment groups were cultured with phorbol 12-myristate 13-acetate (PMA) plus ionomycin in the presence of Brefeldin A before staining
for intracellular expression of IL-4 prior to FACS analysis: cytokine expression (y-axis) was plotted against side scatter (x-axis) and the percentage of DLN cells in the cytokine
positive gate shown and annotated to the right of the plot labels (A). Data pooled from two further independent experiments show the numbers (B–F) and Mean Fluorescence
Intensity (MFI) (G) of spontaneously- (B, D, G) and PMA plus ionomycin-stimulated (C, E, F) IL-4-producing DLN (B, C), CD4 DLN (D, E) and CD4+ DLN (F, G) cells. The bar
represents the mean value of the group where black ⁄P 6 0.05 represents the difference between the OVA + ES-62 + IgG compared with the OVA + ES-62 + anti-IFNc group
whilst grey ⁄P 6 0.05, ⁄⁄P 6 0.01 and ⁄⁄⁄P 6 0.001 are for PBS compared with indicated treatment group (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-
IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from two independent experiments).
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ducing cd, CD4 and CD8 T cells and RORct-expressing DLN cells,
including RORct+CD4+ T cells (Fig. 7C and results not shown). In-
deed, the data from the two neutralising antibody experiments
showed that whilst mice from the OVA, but not OVA + ES-62, group
treated with control IgG exhibited a higher number of DLN cells
producing IL-17 than the PBS group, either spontaneously
(Fig. 7D, upper graph) or following stimulation with PMA plus ion-
omycin (Fig. 7D, lower graph), the OVA + ES-62 group treated with
neutralising anti-IFNc antibodies showed signiﬁcantly upregulated
responses. Likewise, whilst mice from the OVA, but not OVA + ES-
62, group treated with control IgG exhibited higher numbers of
CD4 (Fig. 7E) and percentages of Th17 (IL-17+CD4+, Fig. 7F) cells
following stimulation with PMA plus ionomycin than the PBS con-
trol group, the OVA + ES-62 group treated with neutralising anti-
IFNc antibodies again showed signiﬁcantly upregulated responses
(Fig. 7E, F). Reﬂecting this, analysis of IL-17 mRNA production by
DLN cells in an independent experiment revealed that in vivo
exposure to ES-62 reduced the levels found in the OVA group tothose comparable with levels of IL-17 mRNA found in the PBS or
ES-62 groups (Fig. 7G) and although the levels observed were very
low, this was reﬂected by reduced levels of OVA-speciﬁc IL-17 re-
call responses by DLN cells ex vivo in a further separate experiment
(Fig. 7H). Such suppression of Th17 responses reﬂected, at least in
part, a reduction in the ability of mice to prime Th17 responses as
bmDCs from OVA + ES-62 mice induced signiﬁcantly reduced OVA-
speciﬁc Th17 responses relative to those from the OVA group
(Fig. 7I). This suppression of IL-17 responses is not restricted to
the DLN cells but is also apparent at the site of inﬂammation as
qRT-PCR analysis indicated reductions in the levels of IL-4 and
IL-17, but not IFNc, mRNA in the lungs of mice from the
OVA + ES-62, relative to the OVA, group of mice (Fig. 7J) in a further
independent experiment.
Collectively therefore, the results outlined above provide sup-
port for the proposal that ES-62 is acting to suppress Th17/Th2-
associated airway inﬂammation and consequent pathology, not
by inducing Treg cells but by inducing counter-regulatory IFNc re-
sponses to reset the Th1/Th2/Th17 balance.
Fig. 7. The phosphorylcholine-containing glycoprotein, ES-62, suppresses IL-17 responses in murine ovalbumin (OVA)-induced airway inﬂammation. Pooled draining lymph
node (DLN) cells from the four indicated treatment groups were cultured with medium (A) or phorbol 12-myristate 13-acetate (PMA) plus ionomycin (B) in the presence of
Brefeldin A before staining for intracellular expression of IL-17 prior to FACS analysis: cytokine expression (y-axis) was plotted against side scatter (x-axis) and the percentage
of DLN in the cytokine positive gate shown and annotated to the right of the plots. (C) RORct expressing unstimulated CD4+ T cells from the DLN of pooled mice from the four
treatment groups are shown. The numbers (D) of spontaneously (upper; (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 10; OVA + anti-IFNc, n = 10 and OVA + ES-
62 + anti-IFNc, n = 9; pooled from two independent experiments)) and PMA plus ionomycin-stimulated (lower; (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-62 + IgG, n = 9;
OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from two independent experiments)) IL-17-producing DLN cells and the numbers of IL-17-producing CD4
DLN cells (E) and proportions of IL-17-producing CD4+ cells (F) from PMA plus ionomycin-stimulated DLN cells from individual mice (PBS, n = 6; OVA + IgG, n = 9; OVA + ES-
62 + IgG, n = 9; OVA + anti-IFNc, n = 10 and OVA + ES-62 + anti-IFNc, n = 9; pooled from two independent experiments) are presented; the bar represents the mean value of
the group and grey ⁄P 6 0.05 shows the difference between the PBS and indicated treatment group. In an independent experiment (G), the levels of IL-17 mRNA (against a
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) reference) in the pooled DLN cells from the four indicated treatment groups are shown, normalised to the levels found
in the control PBS group. (H) The levels of IL-17 detected by Luminex following stimulation of pooled DLN cells frommice in each group with medium or OVA (500 lg/ml) in a
further independent experiment are shown and where ⁄⁄⁄P 6 0.001 for triplicate samples. In (I), pooled bone marrow-derived dendritic cells (bmDCs) from OVA and
OVA + ES-62 mice were pulsed with OVA peptide on day 7 and cocultured with DO11.10 Tg CD4+CD62L+ T cells for 72 h before analysing the levels of IL-17 production in
culture supernatants by ELISA. The data are presented as the mean ± S.D. where ⁄⁄P 6 0.01, OVA compared with OVA + ES-62 at 30 nM of OVA peptide and ⁄⁄⁄P 6 0.001, OVA
compared with OVA + ES-62 at 300 nm of OVA peptide in one experiment. In a further independent experiment, (J), the levels of IL-4, IFNc and IL-17 mRNA (against a GAPDH
reference) in the lungs from the OVA + ES-62 group (grey bars) are shown, normalised to the levels found in the OVA group (black bars).
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It was previously shown that prophylactic exposure to ES-62, a
PC-containing glycoprotein secreted by the ﬁlarial nematodeA. viteae, suppresses OVA-induced allergic airway disease in the
mouse (Melendez et al., 2007). Although this protection was asso-
ciated with desensitisation of mast cell responses, ES-62 was also
shown to suppress the Th2 phenotype of the allergic response, as
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lungs. We now show that ES-62 suppresses the lung inﬁltration
by a heterogeneous population of cells, particularly neutrophils, a
phenotype that is associated with severe asthma and is generally
refractory to conventional anti-inﬂammatory therapies, including
steroids (Ito et al., 2008; Iwakura et al., 2011; Yang et al., 2012).
Consistent with the observed inhibition of cells inﬁltrating the
lungs, we also found that exposure to ES-62 suppressed IL-17 re-
sponses, which have recently been shown to play key roles in
recruitment of eosinophils, neutrophils and macrophages as well
as in the promotion of Th2 polarised inﬂammation and develop-
ment of severe asthma (Lajoie et al., 2010; Wang et al., 2010; Iwak-
ura et al., 2011; Barin et al., 2012; Dias and Banerjee, 2012). Such
protection against Th2/Th17-associated airway inﬂammation did
not reﬂect induction of Treg responses (no increased IL-10 or Foxp3
expression) but rather a switch in priming towards increased Tbet
expression and IFNc production. Further support for ES-62 sup-
pressing pathogenic Th2/Th17 responses by inducing counter-
regulatory IFNc responses (Durrant and Metzger, 2010; Jager and
Kuchroo, 2010) was provided by our studies showing that neutral-
ising anti-IFNc antibodies blocked the protection against airway
inﬂammation afforded by ES-62, in terms of cellular inﬁltration
of the lungs as well as airway remodelling, and that this loss of pro-
tection was accompanied by elevated Th2 and Th17 responses.
The anti-inﬂammatory mechanism that is employed by ES-62
was compared with that associated with some other helminths
and their products. It appears to be quite distinct from the ap-
proach utilised by the gastrointestinal (GI) nematode, Heligmo-
somoides polygyrus, which can inhibit OVA-induced airway
inﬂammation in mice via the induction of a Treg cell population
(Wilson et al., 2005). Moreover, there are a number of differences
observed between the immunomodulatory effects of an H. polygy-
rus infection and ES-62 when affording protection. For example,
the GI nematode only inhibited production of Th2 effector cyto-
kines (IL-5/IL-13) whereas ES-62 also had an inhibitory effect on
a cytokine that facilitates Th2 responses, IL-4. This is likely to ex-
plain why, unlike in the H. polygyrus study, we observed a decrease
in IgE levels. We also could not ﬁnd any evidence of increased lev-
els of Treg cells as evidenced by Foxp3 expression or production of
IL-10 in DLN cell cultures from ES-62 exposed animals although
this regulatory cytokine is also not the principal facilitator of the
protective effects of H. polygyrus (Wilson et al., 2005). It is worth
emphasising at this point that our present data are consistent with
our previous work indicating that there is little evidence that ES-62
induces any form of Treg population (Marshall et al., 2005). In
agreement with our observations, recent data (McSorley et al.,
2012) reported a lack of expansion of Tregs upon treatment of
allergic mice with H. polygyrus excretory–secretory (HES) products,
even though administration of HES products at the sensitisation
stage signiﬁcantly diminished numbers of eosinophils and neutro-
phils in BAL and macrophages in the lung. In this respect therefore,
the effects of HES products are similar to those afforded by ES-62.
Importantly, however, treatment with HES products abolished
OVA-induced IFNc, in addition to downregulating IL-4, IL-5 and
IL-13 production, a ﬁnding which appears to rule out the possibil-
ity that HES and ES-62 might share a commonmechanism of action
in suppression of allergic airway inﬂammation.
The immunomodulatory effects being observed with ES-62 are
also comparable to those described when AHR to OVA was inhib-
ited by an extract of the GI nematode, Ascaris suum (Lima et al.,
2002). Here, each of IL-4 and IL-5 in BALF, and IgG1 and IgE in ser-
um was reduced. As with ES-62 (Melendez et al., 2007), airway hy-
per-reactivity to methacholine was also inhibited in this model
system (Lima et al., 2002). One difference from the A. suum study
was that we did not see a reduction in serum IgG1 but we previ-
ously showed a lack of a relationship between the ability of ES-62 to induce IL-4 and promote IgG1 responses to OVA (Marshall
et al., 2005). A decrease in IgE without a decrease in IgG1 could per-
haps reﬂect the activity of IL-10 (Jeannin et al., 1998) but as men-
tioned above we could ﬁnd no evidence for increased IL-10 in our
study. More recently, another ﬁlarial nematode-derived molecule,
cystatin, has been found to protect against OVA-induced airway hy-
per-reactivity, showing many of the properties of ES-62 in reducing
eosinophilia, IgE and IL-4 (Schnoeller et al., 2008). Although similar
to ES-62, the effect of this molecule does not appear to be due to
induction of Tregs, it differs from ES-62 in relying on IL-10 for some
activities. In particular, whilst a role for IL-10-producing macro-
phages is reported in the cystatin study (Schnoeller et al., 2008),
we have found that the spontaneous secretion of IL-10 frommacro-
phages derived from mice with airway disease was reduced in the
group exposed to ES-62 (results not shown).We also found IL-10 re-
sponses to be suppressed by ES-62 throughout this current study
and although such effects are perhaps initially surprising, recent
ﬁndings suggesting that IL-4 and IL-10 are essential for pulmonary
arterial remodelling in response to inhaled Aspergillus allergen in a
mixed Th1/Th2/Th17 microenvironment (Shreiner et al., 2012)
may suggest that this suppression of IL-10 contributes to the protec-
tion afforded by the helminth product.
Whilst the immunoregulatory mechanisms involved have not
been fully delineated, as mentioned earlier, ES-62 appears to act,
at least in part, by resetting the Th1/Th2/Th17 balance by inducing
a switch in priming towards a Th1-like phenotype (relative in-
crease in IFNc and induction of Tbet expression, involving both
CD4+ and CD8+ T cells). Whilst Tbet-expressing induced Tregs have
been reported (Anderson et al., 2006; Cobbold, 2006), it is unlikely
that the induction of Tbet expression by ES-62 reﬂects the genera-
tion of such induced Tregs as these have also been reported to
mediate their effects, at least in part, via IL-10 production which
is, as noted earlier, reduced in the ES-62-treated groups. Moreover,
recent analysis of Tbet/ mice has revealed that dysfunction of
Tbet may be involved in the pathogenesis of allergic airway disease
and that Tbet+CD4+ cells can inhibit Th2-mediated eosinophilia
(Fujiwara et al., 2007). Consistent with this, expression levels of
Tbet appear to be reduced in the airways of asthmatic patients
(Finotto et al., 2002) and polymorphisms in this transcription
factor have been associated with airway inﬂammation and hy-
per-responsiveness (Raby et al., 2006; Munthe-Kaas et al., 2008;
Durrant and Metzger, 2010). Collectively, therefore, these ﬁndings
provide a potential rationale for how resetting of the Th1/Th2
balance associated with increased Tbet and IFNc expression by
ES-62 can suppress airway inﬂammation.
Given that Th17 cells can counter-regulate Th1 development and
that IL-17 family members (IL-17A, F and IL-25 (IL-17E) have been
shown to promote allergic airway inﬂammation (Linden, 2003;
Kawaguchi et al., 2004; Traves and Donnelly, 2008; Wang and Liu,
2008; Durrant and Metzger, 2010; Jager and Kuchroo, 2010), a po-
tentialmechanism for the induction of counter-regulatory IFNc pro-
duction is suggested by our ﬁndings that the ES-62-driven switch in
theTh1/Th2balancewas accompaniedbybothadecrease in thepro-
portionofDLNcells producing IL-17and in theability of bmDCs from
ES-62-treated mice to prime Th17 responses. Intriguingly, we have
recently demonstrated that the ability of ES-62 to protect against
IL-17-dependent Th1-associated autoimmune inﬂammation in the
collagen-induced mouse model of arthritis reﬂected targeting of a
complex (cd T cell, DC and Th17 interactions) cellular network in
which ES-62 suppressed both initiation of, and maintenance of
ongoing, IL-17 responses (Pineda et al., 2012). Indeed, the IL-17-
producing CD4 DLN cell population targeted by ES-62 in this pres-
ent study may include a similar population of IL-17-producing cd T
cells modulated by the helminth product.
Thus, ES-62 may target IL-17 as a mechanism to suppress either
Th1 or Th2 pathology by resetting the Th1/Th2 balance. Support for
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vided by studies demonstrating that the extent of AHR following
exposure to methacholine correlates with the levels of IL-17
(Barczyk et al., 2003; Kolls et al., 2003; Durrant and Metzger,
2010) and consistent with this, we have found that exposure to
ES-62 in vivo substantially suppresses AHR (Melendez et al.,
2007). Moreover, studies on IL-17A- or IL-17RA-deﬁcient mice
showed decreased induction of OVA-speciﬁc T cells, reduced eosin-
ophilic inﬂammation and lower levels of serum IgE (Nakae et al.,
2002; Schnyder-Candrian et al., 2006; Durrant et al., 2009; Durrant
and Metzger, 2010) and may reﬂect our ﬁndings that treatment of
the OVA + ES-62 group with neutralising anti-IFNc antibodies re-
sults in elevated levels of Th2 cells (perhaps reﬂecting the increase
in lymphocyte inﬁltration of the BALF) as well as the increased
neutrophil and macrophage recruitment more normally associated
with elevated Th17 responses. Of particular interest, therefore,
given our ﬁndings with respect to ES-62-mediated induction of
Tbet and resetting of the Th1/Th2 balance, OVA-induced airway
inﬂammation is predominantly Th17-mediated in Tbet-deﬁcient
animals and this inﬂammation can be suppressed by treatment
with IL-12 during the challenge phase (Durrant et al., 2009;
Durrant and Metzger, 2010).
However, it should be noted that IL-17 may also act in sensi-
tised mice to dampen the allergic response by inhibiting chemo-
kine production, eosinophilia and bronchial hyperactivity
(Hellings et al., 2003; Schnyder-Candrian et al., 2006) and that hu-
man hyper-IgE syndrome is associated with a failure in IL-17 pro-
duction by T cells (Ma et al., 2008; Milner et al., 2008). Moreover,
IFNc-producing Th1 cells have been implicated in the development
of severe macrophage-dependent, steroid-resistant asthma (Yang
et al., 2009). However, these pathogenic effects of IFNc are entirely
dependent on crosstalk with endotoxin-driven TLR4/MyD88 pro-
inﬂammatory signalling and we previously showed that ES-62 sub-
verts TLR4/MyD88 (and TLR2/TLR9 but not TLR3 which is MyD88
independent) signalling to an anti-inﬂammatory phenotype and
suppresses MyD88 expression during Th17 development (Good-
ridge et al., 2005; Melendez et al., 2007; Pineda et al., 2012). Taking
these ﬁndings into account, it seems likely that both IFNc and IL-17
might exhibit dual pathogenic and protective roles depending on
the temporal and microenvironmental context of the response.
In conclusion, the ﬁnding that ES-62 acted to suppress Th2 re-
sponses of DLNs to heterologous Ag is consistent with the idea that,
despite biasing immune responses towards a Th2-like phenotype
(Harnett and Harnett, 2010), nematode infections may protect
against atopy. Thus, although ES-62 may have a tendency to pro-
mote a weak Th2-like immunological phenotype in naïve mice
(Houston et al., 2000; Whelan et al., 2000; Marshall et al., 2005),
this does not prevent it inhibiting Th2 responses when they are
contributing to pathological inﬂammation. ES-62 appears to act
to reset the Th1/Th2 balance towards a more ‘‘neutral’’ or anti-
pathologic inﬂammatory phenotype by targeting Th17/IL-17. Inter-
estingly, this resetting of the Th1/Th2 balance is Ag-speciﬁc as
mitogen-induced responses remained unaltered (results not
shown and McInnes et al., 2003): thus, ES-62 can act to limit Th1
or Th2 pathology induced by chronic inﬂammation whilst allowing
the generation of necessary immune responses to remain intact.
Collectively, these studies indicate that ES-62 or, more likely, small
molecule analogues (patent application number 1214106.5) may
have therapeutic potential in asthma, particularly for those sub-
types of patients (e.g. smokers, steroid resistant) who are refrac-
tory to current treatments.
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